CDK9 and inflammatory bowel disease: In summary, using an immune-mediated murine colitis model and colonic lymphocytes from patients with IBD, we demonstrate the therapeutic potential of inhibiting P-TEFb/CDK9, a transcriptional elongation factor downstream of T-bet.